<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="treatment protocol for management of COVID-19 patients, which included moxifloxacin," exact="levofloxacin" post="(consider tolerance) and arbidol administration (8). However, the underlying"/>
 <result pre="potentially effective in treating COVID-19, including oseltamivir, ganciclovir, arbidol and" exact="lopinavir" post="/ ritonavir. Many clinical trials are currently underway to"/>
 <result pre="treated with antiviral agents. The most commonly used antivirals were" exact="lopinavir" post="/ ritonavir, oseltamivir, ribavirin and arbidol, respectively. Route and"/>
 <result pre="The most commonly used antivirals were lopinavir / ritonavir, oseltamivir," exact="ribavirin" post="and arbidol, respectively. Route and duration of administration were"/>
 <result pre="China (12) 9 14 to 56 5 Symptomatic COVID-19 Lopinavir/" exact="Ritonavir" post="9 800 mg/200 mg daily Oral 4 to 11"/>
 <result pre="80 46.10 Â± 15.42 39 All severity ranges of COVID-19" exact="Ribavirin" post="80 NR NR 2-12 days Yes 21 patients were"/>
 <result pre="COVID-19 Lopinavir/ritonavirArbidolLopinavir/ritonavir + Arbidol 25121 Lopinavir 400 mg twice daily" exact="ritonavir" post="100 mg twice dailyArbidol 200 mg three time daily"/>
 <result pre="the MIRACLE trial, was designed to evaluate the efficacy of" exact="lopinavir" post="/ ritonavir and interferon-Î²1b combination therapy in the treatment"/>
 <result pre="trial, was designed to evaluate the efficacy of lopinavir /" exact="ritonavir" post="and interferon-Î²1b combination therapy in the treatment of MERS-CoV"/>
 <result pre="A systematic review and meta-analysis Reviews in medical virology2018283e197729664167 36GrossAEBrysonMLOral" exact="Ribavirin" post="for the Treatment of Noninfluenza Respiratory Viral Infections: A"/>
</results>
